VIR — Vir Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $783.27m
- $276.76m
- $74.21m
- 42
- 24
- 26
- 20
Annual cashflow statement for Vir Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -299 | 529 | 516 | -615 | -522 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 72.8 | 31.2 | 490 | 123 | 148 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 29.5 | -628 | 665 | -305 | -84 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -191 | -47.6 | 1,663 | -779 | -446 |
| Capital Expenditures | -6.55 | -21.8 | -68 | -21.6 | -7.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -3.31 | -119 | -1,125 | 186 | 507 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -9.86 | -141 | -1,193 | 165 | 499 |
| Financing Cash Flow Items | -4.25 | 0 | -1.2 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 529 | 100 | 34.8 | 7.48 | 4.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 329 | -88.1 | 505 | -607 | 57.4 |